Digital Mind-Body Therapy for Neoadjuvant Breast Cancer

Inclusion criteria

• Participants voluntarily agree to take part in this study and provide written informed consent.
• Female, aged ≥18 years.
• Histologically confirmed invasive breast cancer.
• Planned to receive neoadjuvant therapy.
• Completion of psychosomatic assessment prior to initiation of neoadjuvant therapy, with at least two of the following domains reaching mild or higher severity: anxiety, depression, insomnia, or psychological distress (severity classified according to established clinical cut-off values of the respective assessment scales).
• Good compliance and willingness to adhere to follow-up.
• Normal hearing, without severe hearing impairment.
• Possession of a smartphone and ability to independently operate mobile applications.

Exclusion criteria

• Presence of distant metastasis.
• History of other malignancies, except for adequately treated basal cell carcinoma or squamous cell carcinoma of the skin, carcinoma in situ of the cervix, or other cancers with disease-free survival >5 years.
• Immunodeficiency or human immunodeficiency virus (HIV) infection.
• Severe dysfunction of the heart, lungs, liver, or kidneys.
• Uncontrolled infection or active infection.
• Pregnant or lactating women.
• Markedly abnormal psychological or cognitive status that precludes completion of psychosomatic assessment.
• Prior diagnosis of bipolar disorder, schizophrenia, schizoaffective disorder, or other psychiatric disorders secondary to medical conditions.